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Viruses must continually adapt against dynamic innate and adaptive responses of the host immune system to establish chronic
infection. Only a small minority (∼20%) of those exposed to hepatitis C virus (HCV) spontaneously clear infection, leaving
approximately 200 million people worldwide chronically infected with HCV. A number of recent research studies suggest that
establishment andmaintenance of chronicHCV infection involve natural killer (NK) cell dysfunction.This relationship is illustrated
in vitro by disruption of typical NK cell responses including both cell-mediated cytotoxicity and cytokine production. Expression of
a number of activating NK cell receptors in vivo is also affected in chronic HCV infection.Thus, direct in vivo and in vitro evidence
of compromised NK function in chronic HCV infection in conjunction with significant epidemiological associations between the
outcome of HCV infection and certain combinations of NK cell regulatory receptor and class I human histocompatibility linked
antigen (HLA) genotypes indicate that NK cells are important in the immune response against HCV infection. In this review, we
highlight evidence suggesting that selective impairment of NK cell activity is related to establishment of chronic HCV infection.
1. Host Invasion and Immune Evasion
Human immunity is classically divided into innate and
adaptive components. The adaptive immune response is
generally regarded as being uniquely mediated by B and
T lymphocytes, as it is only progenitors of these cells
that undergo somatic recombination-activating gene- (Rag-)
dependent variable (V) gene rearrangement in order to
produce a diverse clonotypic repertoire of antigen-specific
receptors [1]. Antigen-mediated clonal selection, leading to
expansion and persistence of particular cells or their products
at elevated levels, provides the adaptive immune system
with specificity and memory. In contrast, innate immune
responses offer a first line of defense, stemming from cells and
mechanisms that recognize pathogen-associated molecular
patterns (PAMPs) in a generic, nonspecific, and noninstruc-
tive manner [2]. Coexistence of persistent viruses and their
hosts exerts selective pressures on both the host immune
system and on viral genomes, forcing viruses to continually
evolvemechanisms throughwhich host immune defenses are
evaded.
Viral evasion strategies can include antigenic variation,
synthesis of decoy proteins that inactivate immune responses,
production of proteins (immunoevasins) that compromise
antigen presentation, and production or induction of proteins
that disrupt host humoral and cellular immune responses
and/or effector functions [2, 3]. While T-cell-mediated
immune responses provide long-term control of viral infec-
tions, initial management of these infections by natural killer
(NK) cells, prior to development of the adaptive immune
response, is thought to be crucial. In humans, depressed NK
cell function is associated with sensitivity to viral infections
[4]. Of particular note, Biron et al. described the case of a
patient with genetic NK cell deficiency and extreme sensitiv-
ity to herpes virus infections, despite having normal numbers
of B and T lymphocytes [5]. Multiple NK cell studies in the
context of viral infection indicate that viruses evade immune
pressure by generating variants that modulate recognition of
infected cells by NK cells. Furthermore, NK cells are not only
important for direct early control of viral infections, but they
also contribute to induction of the adaptive antiviral immune
response by releasing immunomodulatory cytokines and
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chemokines [6] and through bidirectional interactions with
dendritic cells (DC) (reviewed in [7, 8]). These reciprocal
interactions ultimately drive the T-cell immune response
and, in some cases, culminate in reduced viral replication
or even clearance of viral infection [9]. Recent studies also
demonstrate that murine and possibly human NK cells
have receptors specific for cytomegalovirus (CMV) that
enable selective proliferation and expansion of NK subsets,
thus endowing NK cells with limited properties previously
attributed exclusively to T and B lymphocytes [10–13].
Epidemiological studies suggest that NK cells play a role
in determining the outcome of hepatitis C virus (HCV)
infection [14, 15]. Here, we will consider the effects HCV
infection has uponNK cells by reviewing the epidemiological
associations, noting in vivo evidence ofNKcell dysfunction in
chronic HCV infection and discussing recent in vitro exper-
iments indicating that direct interaction between circulating
NK cells and HCV-infected cells impairs NK cell function.
2. Hepatitis C Virus
Approximately 3% of the world’s population is infected with
HCV [16], an enveloped, positive-sense RNA virus of the
Hepacivirus genus within the Flaviviridae family [3]. The
HCV RNA genome is encased by core protein multimers
to form the viral nucleocapsid that is surrounded by an
endoplasmic reticulum (ER) membrane-derived envelope
studded with HCV envelope proteins 1 and 2 (E1/E2) [17, 18].
Host cell infection with HCV occurs through the interaction
of HCV E1 and/or E2 with multiple cellular coreceptors
including CD81 (also termed target of antiproliferative anti-
body 1 (TAPA1)) [19–23], scavenger receptor class B type
I (SRBI) [24–26], occludin (OCLN) [27–29], and claudin-
1 (CLDN1) [30, 31]. In the absence of effective treatment,
approximately 80% of individuals infected with HCV fail
to mount an immune response adequate for viral clearance
and, consequently, develop chronic infection and suffer an
increased risk for liver fibrosis and hepatocellular carci-
noma [32–34]. While approximately 20% of HCV-infected
individuals spontaneously clear infection, the mechanism of
spontaneous clearance remains poorly defined and a greater
understanding of both the viral clearance process and of
viral strategies underlying immune escape is necessary for
future vaccine development and more effective management
of infection. There is mounting evidence that NK cells are
involved in the clearance and control of HCV infection,
including associations between NK cell dysfunction, chronic
HCV infection, and the pathogenesis of liver disease [14, 35,
36].
Natural killer cells are lymphocytes that develop in the
bone marrow, differentiate in lymphoid tissues, and migrate
into various tissues [37]. The environment in which a NK
cell matures impacts NK cell phenotype and function giving
rise to a heterogeneous population. Although NK cells can
be prominent in nonlymphoid tissues such as the liver
and decidua [38–40], the functions of these NK cells can
differ greatly from the functions of those in peripheral
blood. The NK cells that comprise between 5 and 20%
of peripheral blood lymphocytes provide inherent defense
against some transformed cells and a variety of pathogens,
including viruses [5, 41–43]. First identified in 1975 and
classically defined as cytolytic lymphocytes, NK cells remain
categorized as innate immune effector cells since they do
not undergo receptor gene rearrangement [41, 44]. Thus,
selective effector function against infected or transformed
cells is mediated by composite integration of signals received
through a diverse assortment of germ-line encoded activating
and inhibitory receptors interacting with their respective
ligands [45] (Figure 1).
3. Natural Killer Cell Functions
Peripheral NK cells primarily fall into two major func-
tionally distinct subsets. The highly cytotoxic “mature”
CD56dimCD16bright NK cells are more responsive to cell
surface ligands than the “immature” CD56brightCD16dim
NK cells, which are more responsive to soluble factors [6,
46]. The CD56brightCD16dim NK cells are less cytotoxic but
predominantly secrete cytokines, such as proinflammatory
interferon- (IFN-) 𝛾 and tumour necrosis factor- (TNF-) 𝛼,
or immunoregulatory interleukin- (IL-) 10 [47, 48].
Through their constellation of cell surface receptors,
NK cells can detect variations in cell surface composition
manifest through a multitude of ligands and integrate this
information to determine the type and intensity of response
that is appropriate [49]. With no prior exposure, NK cells
can recognize and kill target cells that have downregulated
expression of class I human histocompatibility-linked leuko-
cyte antigen- (HLA-) I molecules, a process that occurs dur-
ing many viral infections [45]. In humans, the NK receptors
that recognize class I HLA molecules, predominantly killer
cell immunoglobulin-like receptors (KIR), can convey NK
cell activating signals through short (S) cytoplasmic domains
or NK cell inhibitory signals if the KIR possesses a long (L)
cytoplasmic domain [50] (see Figure 3). Inhibitory NKG2A
receptors can also prevent cytolysis of healthy cells by rec-
ognizing expression of nonclassical class I HLA-E complexes
[45, 51–53]. As per the “missing self ” hypothesis, healthy
cells expressing normal amounts of class I HLA complexes
are less sensitive to NK cell lysis than are transformed or
virus-infected cells with decreased HLA-I expression [54]
(Figure 2). Virus-infected cells expressing adequate amounts
of class I HLA molecules generally remain protected from
NK cell-mediated lysis. Therefore, maintaining expression of
class I HLA molecules, especially HLA-E, is one mechanism
by which pathogens can thwart NK cell surveillance.
4. Natural Killer Cells in HCV Infection
Natural history studies have revealed thatHCV-exposed indi-
viduals with coordinate expression of certain KIR variants
and their corresponding HLA-I ligand gain a higher prob-
ability of spontaneous HCV clearance than those without
[14, 55–58]. To maintain functional recognition of rapidly
evolving class I HLA complexes, the NK cell KIR genes
must also evolve under pathogen-mediated pressure [59, 60].
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Figure 1: Natural killer cell natural cytotoxicity. NK cell inhibitory receptors recognize “self ” MHC-I molecules which can prevent cytolysis
of healthy cells evenwhen activating receptors interact with their ligands. Transformed or virus-infected cells often reduceMHC-I expression;
thus when a NK cell activating receptor engages its ligand, there is no negative signal to overcome the positive activating signal and the target
cell is destroyed through a perforin and granzyme apoptosis-inducing mechanism.
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Figure 2: Natural killer cell receptor repertoire. Natural killer cells express some fraction of a diverse set of germ-line encoded receptors,
many of which display allelic polymorphism. They are variously associated with different adaptor molecules that convey either activating or
inhibitory signals. Two of the three natural cytotoxicity receptors, NKp30, NKp46, and also the CD16 Fc
𝛾
RIII receptor, mediate signaling
through ITAM-containing 𝜁 chain homodimers, Fc
𝜀
RI
𝛾
homodimers, or Fc
𝜀
RI
𝛾/𝜁
heterodimers. Activating receptors depicted here are CD16,
NKp30, NKp46, NKp44, KIR3DS1, CD160, and NKG2D; inhibitory receptors depicted are TIM-3 and NKG2A/CD94.The CD56 molecule is
comprised of five immunoglobulin-like domains and, in the absence of CD3, is a reliable marker for NK cells.
Genotyping of those exposed to HCV demonstrated that
coordinate expression of NK cell receptor KIR2DL3 and its
cognate class I HLA C group 1 (HLA-C1) ligand confers an
increased likelihood of spontaneous HCV clearance or of
a sustained virological response (SVR) to treatment when
spontaneous HCV clearance is not achieved [14, 56, 61].
One functional interpretation of this association is that as
the interaction between KIR2DL3 and HLA-C1 is relatively
low affinity, it generates a weaker inhibitory signal than
other KIR/ligand interactions allowing a greater functional
response by NK cells [57, 58]. Other KIRs that have been
identified as relevant to the outcome of HCV infection and
treatment efficacy are 2DL2, 2DL3, 2DS1, 2DS2, and 3DL1 [61,
62]. The expression of KIR3DL1 is decreased in individuals
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Figure 3: Natural killer cell antibody-dependent cell-mediated cytotoxicity (ADCC). Natural killer cells can recognize and kill antibody-
coated target cells. When antibodies bind antigens displayed on the surface of transformed or infected target cells, NK CD16 receptors bind
the Fc portion of bound antibodies (most IgG subclasses) andmediate cytotoxicity against the target cell by degranulation and directed release
of cytotoxins.
with HCV infection, suggesting that this receptor may also
be involved in the regulation of chronic HCV infection [55].
Expression of KIRs with short cytoplasmic tails promotes
target cell cytolysis and IFN-𝛾 production through DAP12
signaling (see Figure 2) upon recognition of cognate class
I HLA ligands [50, 63, 64]. Although the precise nature
of its HLA ligand has yet to be identified, the activating
receptor KIR3DS1 appears to support protection against
hepatocellular carcinoma in those chronically infected with
HCV and favors HCV genotype 1a clearance in response to
combination treatment with ribavirin and pegylated IFN-𝛼
[63, 65]. Favourable genetic combinations of KIR and class
I HLA complexes contribute to the NK cell response not
only in acute HCV infection, but also towards controlling
disease progression in those chronically infected and towards
sustained virological responses in those receiving treatment.
Viruses can evade the NK cell immune response through
the generation of variants that can escape stimulatory and/or
enhance inhibitory NK cell receptor (NKR) recognition.
Some studies indicate that the HLA-E molecule, which
is a ligand for the NK inhibitory receptor NKG2A, is
upregulated on hepatocytes in complex with an HCV core
protein peptide (aa35–44) during chronic HCV infection
[66]. Nattermann et al. reported an increased expression of
NKG2A/CD94 inhibitory receptors on circulating NK cells
in patients with chronic HCV infection; however, in an in
vitro model representative of acute HCV infection, neither
NKG2A nor HLA-E expression increased on NK or HCV-
infected cells, respectively [67–69]. Nonetheless, to combat
NK cell-mediated control of infection, HCV may employ
multiple means of increasing expression of natural or decoy
ligands for inhibitoryNKRs as chronic infection develops and
disease progresses.
Since viral infection often results in reduced cell surface
class I HLA expression, NK cell inhibitory signals will be
dampened, allowingNK cells to lyse altered autologous target
cells if activating receptors such as the natural cytotoxicity
receptors (NCRs) NKp46, NKp44, NKp30, or NKG2D or
nonclassical class I HLA-E-specific NCRs CD94/NKG2C and
CD94/NKG2E are engaged (see Figure 2) [45, 70–75]. In
addition, CD16 (Fc𝛾RIII) is a low-affinity activating receptor
specific for the constant (Fc) region of immunoglobulin
G (IgG) that triggers antibody-dependent cell-mediated
cytotoxicity (ADCC) upon recognition of antibody-coated
cells (Figure 3) [45]. The only NCR ubiquitously expressed
on NK cells is NKp46, and while NKp30 and NKp46
are constitutively expressed on subsets of NK cells, NCR
NKp44 expression is restricted to activated NK cells [72,
76]. Many ligands of viral origin have been identified for
NK activating receptors, which can serve as decoys and
disrupt positive NK cell stimuli. Of note, human (H)CMV
capsid protein pp65 disruptsNKp30 expression and influenza
hemagglutinin (HA) can interact with, and inhibit, NK cells
through NKp30, NKp44, and NKp46 [77–79]. Although no
NCR ligands resulting from HCV infection have yet been
identified, studies have reported decreased NK cell activating
receptor expression on NK cells from chronically infected
individuals. A progressive increase in the proportion of
NKG2C+ NK cells was reported to occur following liver
transplantation for chronic hepatitis C and was initially
thought to be associated with HCV recurrence [80]. A
similar NK subset observed in human immunodeficiency
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virus infection expressed reduced levels of the NCRs NKp30,
NKp44, and NKp46 [81]. Expansion of this CD57+NKG2C+
NK subset has since been shown to relate primarily to CMV
infection and involve selection of NK cells expressing KIR
capable of licensing NK effector function and enforcing self-
tolerance [82, 83]. Despite evidence for downregulation of
NCRs on this NK subset, they are polyfunctional in terms of
cytokine expression and demonstrate enhanced cytotoxicity
against antibody-coated target cells [82, 84].
Freshly isolated peripheral blood and liver-derived NK
cells from chronically infected HCV patients exhibited sig-
nificantly lower levels of NCR NKp30 and NKp46 expression
than the NK cells of healthy controls [67]. Although no
differences in NKG2C or NKG2D surface expression were
noted, some in vitro experimental data suggested downreg-
ulated NKG2D and/or NKp30 surface expression after ex
vivo exposure of NK cells to HCV-infected cells [68, 69].
Direct contact between NK cells and HCV-infected cells in
vitro promotes downregulation of NKp30, suggesting that
HCV can affect NK cell recognition and function through
upregulation of an as yet unidentified ligand that physically
interacts withNKp30 [69].This possibility is supported by the
demonstration of increased binding of recombinant NKp30
protein to HCV-infected Huh-7.5 cells [69]. Cytotoxicity and
IFN-𝛾 production by NK cells are also reduced following
short (5 hours) or extended (18 hours) exposure to HCV-
infected Huh-7.5 cells [67–69, 85, 86].
Both NKR expression itself and/or variation in NKR
ligand expression can impact NK cell functions. The T-
cell immunoglobulin mucin-3 (TIM-3) receptor was recently
shown to inhibit cytotoxic and cytokine responses of NK cells
upon interaction with galectin-9 (Gal-9) or phosphatidylser-
ine (PtdSer) on target cells [87–92]. AsGal-9 binding depends
on recognition of certain carbohydrates and the extent of NK
cell receptor ectodomain glycosylation can vary, the degree
of ligand recognition and binding may also vary, thereby
providing another level of regulatory control over NK cell
functions [93–95]. Circulating levels of the Gal-9 ligand
for NK cell TIM-3 receptors are significantly increased in
HCV-infected individuals compared to uninfected controls
[96]. As this interaction mediates an inhibitory response,
this is another potential mechanism through which HCV
can inhibit typical NK functions to favor establishment of
persistent infection.Whilemany studies have investigated the
suppressive effect of TIM-3 in the context of effector T-cell
functions onHCV infection, the impact of TIM-3 onNK cells
with respect to HCV infection has not yet been extensively
studied [84, 85].
Several previous studies investigating the role of NK cells
in HCV infection focused on interactions between HCV E2
and CD81 on NK cells as a potential mechanism underlying
NK cell dysfunction [97–99]. These studies exposed IL-2-
stimulated or purified NK cells to soluble and immobilized
recombinant HCV E2, anti-CD81 monoclonal antibodies,
or plate-bound cell culture-derived HCV (HCVcc) [97, 98].
Engaging NK CD81 in these ways decreased IFN-𝛾 produc-
tion and NK cell cytotoxicity; therefore, cross-linking of NK
CD81 by HCV E2 has been proposed as an NK inhibitory
mechanism promotingHCVpersistence [100–103]. However,
more recent studies reported no significant change in NK cell
cytotoxicity when NK cells were exposed to intact, infectious
cell-free HCVcc at supraphysiological levels [69, 99]. These
results suggest that although HCV E2 may specifically bind
to CD81 on NK cells, the configuration of E2 within an
intact infectious virus particle does not facilitate the degree
of NK CD81 receptor cross-linking necessary to mediate
an inhibitory signal [97, 98]. Most of these systems used
peripheral NK cells stimulated in vitro with recombinant
IL-2 (rIL-2), rIL-12, or IFN-𝛼 combined with extended
coculture with HCV-infected cells, introducing additional
complications to interpreting in vivo relevance of the reported
effects [67, 68, 97, 98, 104].
One recent study used the monoclonal antibody AP33,
a broadly neutralizing antibody against the CD81-binding
site on HCV E2 (amino acid residues 412–423) [105–107], in
conjunction with HCV-infected human hepatoma (Huh-7.5)
and unadulterated NK cells to prevent E2/CD81 interactions
and probe the significance of NK CD81/HCV E2 interactions
in the context of NK cell inhibition. Firstly, there was no evi-
dence of cell surface expression of HCV E2 on HCV-infected
Huh-7.5 cells, and secondly, blocking potential HCV E2/NK
CD81 interactions with either AP33 or soluble anti-CD81
had no significant effect on NK cell inhibition mediated by
HCV-infected cells. These data provide compelling evidence
that an HCV E2/NK CD81 interaction does not underlie the
inhibition ofNK cytotoxicitymediated byHCV-infected cells
in vitro [69, 99].
Chronic viral infection requires successful evasion of
innate and adaptive host immune responses. Through inter-
action with host innate and adaptive immune responses,
HCV has evolved mechanisms to circumvent immune pres-
sures and to establish chronic infection in the majority
of cases. Numerous experimental studies demonstrate NK
cell dysfunction in HCV infection and epidemiological data
suggests that NK cells play some role in clearance or control
of HCV infection [14, 35, 36, 69]. Since NK cells uniquely
bridge innate and adaptive immune responses, their sufficient
function may be especially important in initial and lasting
control of HCV infection.
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